Business Description
Parabilis Medicines Inc
NAICS : 325412
SIC : 2834
ISIN : US6989551014
Description
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.47 | |||||
Equity-to-Asset | -0.2 | |||||
Debt-to-Equity | -3.55 | |||||
Debt-to-EBITDA | -0.41 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.4 | |||||
9-Day RSI | 62.91 | |||||
14-Day RSI | 57.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.52 | |||||
Quick Ratio | 0.52 | |||||
Cash Ratio | 0.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -731 | |||||
ROA % | -126.82 | |||||
ROIC % | -194.92 | |||||
ROC (Joel Greenblatt) % | -291.64 | |||||
ROCE % | -204.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -31.55 | |||||
EV-to-EBITDA | -32.11 | |||||
EV-to-FCF | -36.73 | |||||
Earnings Yield (Greenblatt) % | -3.17 | |||||
FCF Yield % | -3.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PBLS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Parabilis Medicines Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.81 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 57.05 | ||
| 14-Day ATR ($) | 2.68898 | ||
| 20-Day SMA ($) | 29.532 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 24.51 - 34.4706 | ||
| Shares Outstanding (Mil) | 122.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Parabilis Medicines Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Parabilis Medicines Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Parabilis Medicines Inc Frequently Asked Questions
What is Parabilis Medicines Inc(PBLS)'s stock price today?
The current price of PBLS is $32.84. The 52 week high of PBLS is $34.47 and 52 week low is $24.51.
When is next earnings date of Parabilis Medicines Inc(PBLS)?
The next earnings date of Parabilis Medicines Inc(PBLS) is .
Does Parabilis Medicines Inc(PBLS) pay dividends? If so, how much?
Parabilis Medicines Inc(PBLS) does not pay dividend.
Guru Commentaries on NAS:PBLS
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Parabilis Medicines Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers